Related Experiment Video

Updated: Jul 15, 2026

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery
04:48

Noninvasive Determination of Vortex Formation Time Using Transesophageal Echocardiography During Cardiac Surgery

Published on: November 28, 2018

The greying of cardiology: implications for management

Nanette K Wenger

    Heart (British Cardiac Society)
    |April 3, 2007
    PubMed

    Insights

    New cardiovascular therapies and devices must prioritize the needs of elderly patients, who represent the primary user group. Research and development should focus on geriatric cardiovascular care to ensure effective and relevant treatments.

    Area of Science:

    • Geriatric Medicine
    • Cardiovascular Research
    • Biomedical Engineering

    Background:

    • Cardiovascular diseases disproportionately affect the elderly population.
    • Current medical devices and therapies may not adequately address the unique physiological needs of older adults.
    • The aging global population necessitates a shift in healthcare development focus.

    Discussion:

    • The efficacy and safety of cardiovascular interventions in elderly patients require specific consideration.
    • Age-related physiological changes impact drug metabolism, device compatibility, and treatment outcomes.
    • Clinical trials must include diverse geriatric populations to ensure generalizability.

    Key Insights:

    • Therapeutic and device development must align with the demographic realities of patient populations.
    • Elderly patients are the predominant users of cardiovascular treatments and devices.
    • A patient-centric approach prioritizing geriatric needs is crucial for advancing cardiovascular medicine.

    Outlook:

    • Future cardiovascular research should emphasize age-specific formulations and device designs.
    • Enhanced clinical guidelines are needed for geriatric cardiovascular care.
    • Innovation in cardiovascular therapies must be driven by the needs of the aging demographic.

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    Cardiomyopathy VI: Nursing Management01:29

    Cardiomyopathy VI: Nursing Management

    Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...